{"Clinical Trial ID": "NCT00075270", "Intervention": ["INTERVENTION 1:", "Lapatinib with paclitaxel", "Participants received lapatinib 1500 milligrams (mg) orally once daily (OD) with paclitaxel 175 mg/m2 squared (m^2) intravenously (IV) over 3 hours every 3 weeks. The treatment group was stratified by metastatic disease sites and disease stage.", "INTERVENTION 2:", "Placebo with paclitaxel", "The treatment group was stratified by metastatic disease sites and stage of disease. Participants were treated until disease progression, unacceptable toxicity or withdrawal of consent."], "Eligibility": ["\u2022 Inclusion criteria:", "Signed informed consent", "\u2022 Capable of swallowing an oral medicine", "- Cardiac ejection fraction in the institutional range of normal measured by echocardiogram", "Adequate renal and hepatic function", "Adequate bone marrow function", "\u2022 Tumor tissue available for testing", "However, patients should have received cumulative doses of doxorubicin less than 360 mg/m2, 720 mg/m2 of epirubicin or 72 mg/m2 of mitoxantrone.", "No overexpression of Her2/neu in the tumour tissues tested or unknown condition if tissues have never been tested", "- Exclusion criteria:", "Prior treatment of advanced or metastatic breast cancer.", "\u2014 Pregnant or lactating", "Conditions that would have an effect on oral drug absorption", "Active infection", "- Brain metastases", "Treatment with the Endothelial Growth Factor Receptor (EGFR).", "\u2022 Known hypersensitivity to taxol or taxol excipients", "\u2022 Peripheral neuropathy of grade 2 or higher is not allowed", "\u2022 Severe cardiovascular disease or heart disease requiring a device.", "A serious medical or psychiatric disorder that interferes with the patient's safety or informed consent."], "Results": ["Performance measures:", "Time of progression as assessed by the investigator", "The time of progression (TTP) is defined as the interval between the date of randomization and the earliest date of progression of disease (PD) or death due to breast cancer. The investigator evaluated the RFP against the radiological RFP (imaging data) and the symptomatic clinical progress (criteria for assessing responses in solid tumours [RECIST] Criteria: target injury (TL), increase of at least 20% in the sum of the largest diameter (LD) of LT or occurrence of one or more new lesions; non-TL (NTL), occurrence of one or more new lesions and/or unequivocal progression of existing LT.", "Time frame: randomization to date of disease progression or death (mean 26 weeks)", "Results 1:", "Title of the arm/group: Lapatinib with Paclitaxel", "Arm/group description: Participants received lapatinib 1500 milligrams (mg) orally once daily (OD) with paclitaxel 175 mg/m2 squared (m^2) intravenously (IV) over 3 hours, every 3 weeks.", "Total number of participants analysed: 291", "Median (interquartile range)", "Unit of measure: weeks 29.0 (13.9 to 46.9)", "Results 2:", "Title of the arm/group: Placebo with Paclitaxel", "The treatment group was stratified by metastatic disease sites and disease stage.", "Total number of participants analysed: 288", "Median (interquartile range)", "Unit of measurement: weeks 22.9 (12.0 to 38.3)"], "Adverse Events": ["Undesirable Events 1:", "Total: 103/293 (35.15 per cent)", "Neutropenia 22/293 (7.51%)", "Febrile neutropenia 10/293 (3.41%)", "Disseminate intravascular coagulation 0/293 (0.00 %)", "- Leucopenia 0/293 (0.00 %)", "Thrombocythemia 1/293 (0.34%)", "- Left ventricular dysfunction 2/293 (0.68%)", "Atrial fibrillation 1/293 (0.34%)", "Cardiac arrest 1/293 (0.34%)", "- Heart failure 1/293 (0.34%)", "Myocardial infarction 0/293 (0.00 %)", "Adverse Events 2:", "Total: 63/286 (22.03 per cent)", "Neutropenia 14/286 (4.90 per cent)", "- Febrile neutropenia 3/286 (1.05%)", "Intravascular coagulation disseminate 1/286 (0.35%)", "- Leucopenia 1/286 (0.35%)", "- Thrombocytaemia 0/286 (0.00 %)", "- Left ventricular dysfunction 1/286 (0.35%)", "Atrial fibrillation 0/286 (0.00 %)", "Cardiac arrest 0/286 (0.00 %)", "Heart failure 0/286 (0.00 %)", "Myocardial infarction 1/286 (0.35%)"]}